Wet Macular Degeneration: A Patient Guide
At a Glance
Wet macular degeneration can change central vision quickly when fragile blood vessels leak beneath the retina. Prompt injections that block abnormal vessel growth and regular scans can often stabilize vision and limit further damage, although established scarring or tissue loss may not be reversible.
Wet age-related macular degeneration (wet AMD) is a condition that occurs when the body’s age-related retinal and choroidal changes, combined with an imbalance of inflammatory and angiogenic signals, lead to the growth of abnormal, fragile blood vessels beneath the retina. These new vessels are prone to leaking fluid and blood into the macula, the specialized part of the eye responsible for the sharp, central vision you use for reading, driving, and recognizing faces [1]. While this process can lead to rapid changes in your sight, the defining characteristic of modern wet AMD care is that it is highly treatable. With prompt medical intervention, many patients are able to stabilize their vision, reduce leakage, and lower the risk of further vision loss, though treatment may only stabilize vision and cannot reliably reverse established scar or atrophy [2].
The standard of care for managing this condition involves regular injections of medications known as anti-VEGF agents. These treatments work by blocking the specific protein that signals these leaky vessels to grow, effectively “drying out” the retina and preventing further damage to the delicate light-sensing cells [3]. Because the underlying tendency to grow these vessels remains, wet AMD is managed as a chronic condition rather than a one-time event. This means that long-term success depends heavily on adherence to an individualized, scheduled regimen of monitoring and treatment. Even when your vision feels stable, regular scans are essential because they allow your specialist to detect and treat microscopic leaks before they cause permanent scarring [4][5].
Living with wet AMD requires a partnership between you and your clinical team, centered on vigilance and rapid communication. It is completely normal to feel anxious about injections or fearful of vision loss. The most critical moments in your care often happen at home, where noticing a new waviness in straight lines or a sudden “smudge” in the center of your gaze serves as an early warning system. By responding immediately to these changes and maintaining your appointment schedule, you can take control of the disease’s progression. While the diagnosis marks a significant change, the availability of advanced therapies means that preserving your visual function is a realistic goal [2][6].
Urgent Symptoms Action Box
If you experience any of the following, do not wait for your next appointment. Seek same-day advice from your eye team or emergency care if the clinic cannot be reached:
- New distortion or wavy lines
- A new central blur or blind spot
- Sudden vision loss
- New flashes of light or a sudden shower of floaters
- A dark curtain or shadow moving across your vision
If You Miss or Cannot Afford an Appointment:
We understand that the treatment burden is high and transportation or cost barriers happen. A missed appointment does not automatically mean irreversible blindness, but do not simply wait for the next month. Contact your clinic as soon as possible to reschedule and ask to speak with a social worker about transportation or financial assistance.
In this guide
6 chapters
Understanding the Biology of Wet AMD
Learn how wet AMD develops from dry AMD, why VEGF causes abnormal vessels and retinal leakage, and how OCT scans detect fluid and guide close monitoring.
Recognizing Symptoms and Understanding Progression
Learn to recognize wet AMD symptoms such as wavy lines, central blind spots, and slower reading, plus how PCV, OCT scans, and prompt care affect progression.
Monitoring Your Progress: Scans and Tests
Learn how OCT and angiography monitor wet AMD, detect retinal fluid, and guide injection timing, including what a “dry” scan means for ongoing treatment.
Treating Wet AMD: Injections and Strategies
Learn how wet AMD injections work, including anti-VEGF medicines, treat-and-extend schedules, PDT for PCV, treatment risks, and warning signs after treatment.
Injections: What to Expect and Safety Red Flags
Learn what to expect from wet AMD injections, including normal side effects, aftercare, and emergency warning signs that need same-day eye evaluation.
Staying on Track: Life with Wet AMD
Learn how to manage wet AMD between injections, protect your vision, reduce missed visits, use AREDS2 safely, and adapt daily life with low-vision tools.
Common questions in this guide
What is wet macular degeneration?
How do anti-VEGF injections treat wet AMD?
Why do I need scans if my vision feels stable?
Which vision changes need same-day medical attention?
How often will I need treatment for wet AMD?
What should I do if I miss or cannot afford an appointment?
Can wet AMD treatment restore vision that I have already lost?
Get notified when new evidence is published on wet macular degeneration.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (6)
- 1
Macular neovascularization.
Sheth JU, Stewart MW, Narayanan R, et al.
Survey of ophthalmology 2025; (70(4)):653-675 doi:10.1016/j.survophthal.2024.08.003.
PMID: 39222802 - 2
Novel approach to antiangiogenic factors in age-related macular degeneration therapy.
Samelska K, Kupis M, Izdebska J, et al.
Central-European journal of immunology 2022; (47(1)):117-123 doi:10.5114/ceji.2022.113103.
PMID: 35600160 - 3
Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison.
Zhang Y, Gao S, Li X, et al.
Frontiers in pharmacology 2021; (12()):797108 doi:10.3389/fphar.2021.797108.
PMID: 34992542 - 4
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
Ramakrishnan MS, Yu Y, VanderBeek BL
JAMA ophthalmology 2020; (138(3)):237-242 doi:10.1001/jamaophthalmol.2019.4577.
PMID: 32027349 - 5
Reactivation of stable neovascular age-related macular degeneration following treat-and-extend regimen discontinuation.
Artiaga JCM, Wong SW, Menon D, et al.
Clinical & experimental ophthalmology 2025; (53(1)):76-83 doi:10.1111/ceo.14444.
PMID: 39354837 - 6
Optical Coherence Tomography-Angiography of Different Choroidal Neovascularization Subtypes in Wet Age-related Macular Degeneration.
Stavrev VN, Sivkova NP, Koleva-Georgieva DN
Folia medica 2019; (61(2)):317-326.
PMID: 31301657
This page is for informational purposes only and does not constitute medical advice. Your eye-care team should interpret your scans and advise you about injections or urgent vision changes.